Mr. Julius Kalcevich reports

CYTOPHAGE ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT AND FILING OF Q3 FINANCIALS

Cytophage Technologies Ltd. has closed the rest of its previously announced non-brokered private placement. The full details of the offering were announced in a press release dated Oct. 17, 2025. In connection with the closing, the company raised an additional $198,000 of gross proceeds by issuing a total of 990,000 units to investors, to bring the total gross proceeds to $1.2-million.

Each unit, priced at 20 cents, consists of one common share of the company and one-half of a common share purchase warrant. Each whole warrant entitles the holder thereof to purchase one additional share at a price of 40 cents per warrant share for a period of 24 months from the date of issuance. Cytophage may accelerate the expiry of the warrants if the volume-weighted average trading price of its common shares on the TSX Venture Exchange equals or exceed 60 cents for a period of 10 consecutive trading days. In the event that Cytophage exercises the acceleration right, it will do so by providing notice to all holders of warrants.

In connection with the closing, the company has also agreed, subject to receiving exchange approval, to pay finders' fees of $4,200 in cash and 21,000 broker warrants, on the same terms as the warrants forming part of the offering, to qualified non-related parties. In accordance with the rules and policies of the exchange and applicable Canadian securities laws, all securities issued in connection with the closing are subject to a four-month hold period.

The net proceeds of the offering will be used by the company to advance its cutting-edge phage technology in human health, animal health and food security, as well as for general corporate purposes. The closing of the offering remains subject to all regulatory approvals from the TSX Venture Exchange.

The company also wishes to announce the filing of its financial results for the third quarter ended Sept. 30, 2025. The quarterly financial statements and management's discussion and analysis are available to be viewed and downloaded under Cytophage's SEDAR+ profile.

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization.

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular- or organism-level defences. They are nature's version of antibiotics.

Cytophage is improving bacteria's natural predators with environmental, as well as genetic, modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health which offers a fast track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of phage strains, Cytophage is committed to addressing the global challenge of antibiotic resistance. The World Health Organization predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 European Union countries, United States, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products.

Cytophage is using a derisked and patented technology to advance innovative and cost-competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.